Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes.
Journal Article (Journal Article)
The safety and efficacy of anti-diabetic drugs are critical for maximizing the beneficial impacts of well-controlled blood glucose on the prognosis of individuals with COVID-19 and pre-existing type 2 diabetes (T2D). Metformin is the most commonly prescribed first-line medication for T2D, but its impact on the outcomes of individuals with COVID-19 and T2D remains to be clarified. Our current retrospective study in a cohort of 1,213 hospitalized individuals with COVID-19 and pre-existing T2D indicated that metformin use was significantly associated with a higher incidence of acidosis, particularly in cases with severe COVID-19, but not with 28-day COVID-19-related mortality. Furthermore, metformin use was significantly associated with reduced heart failure and inflammation. Our findings provide clinical evidence in support of continuing metformin treatment in individuals with COVID-19 and pre-existing T2D, but acidosis and kidney function should be carefully monitored in individuals with severe COVID-19.
- Cheng, X; Liu, Y-M; Li, H; Zhang, X; Lei, F; Qin, J-J; Chen, Z; Deng, K-Q; Lin, L; Chen, M-M; Song, X; Xia, M; Huang, X; Liu, W; Cai, J; Zhang, X-J; Zhou, F; Zhang, P; Wang, Y; Ma, X; Xu, Q; Yang, J; Ye, P; Mao, W; Huang, X; Xia, J; Zhang, B-H; Guo, J; Zhu, L; Lu, Z; Yuan, Y; Wei, X; She, Z-G; Ji, Y-X; Li, H
- October 6, 2020
Volume / Issue
- 32 / 4
Start / End Page
- 537 - 547.e3
Pubmed Central ID
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)
- United States